Enhanced Selective Inhibitors of Exon 20 Insertion Mutant EGFR for Cancer Treatment
Legal Citation
Summary of the Inventive Concept
This inventive concept presents a series of improvements and enhancements to the original selective inhibitor of exon 20 insertion mutant EGFR, offering targeted delivery, reduced systemic toxicity, and improved bioavailability for more effective cancer treatment.
Background and Problem Solved
The original patent disclosed a method for treating malignant lung tumors using a selective inhibitor of exon 20 insertion mutant EGFR. However, the original patent had limitations in terms of systemic toxicity and bioavailability. This new inventive concept addresses these limitations by introducing targeted delivery systems, improved formulations, and enhanced detection methods.
Detailed Description of the Inventive Concept
The new claims introduce a system for treating EGFR-related cancers, comprising a selective inhibitor of exon 20 insertion mutant EGFR formulated for targeted delivery to tumor cells with reduced systemic toxicity. Additionally, a method for identifying patients likely to respond to EGFR-targeted therapy is disclosed, which involves detecting the presence of exon 20 insertion mutations in EGFR and selecting patients with such mutations for treatment. Furthermore, a pharmaceutical composition with enhanced bioavailability and a kit for diagnosing EGFR-related cancers are also presented.
Novelty and Inventive Step
The new claims introduce the concept of targeted delivery and improved formulations, which are not obvious from the original patent. The inventive step lies in the combination of the selective inhibitor with targeted delivery systems and improved formulations, resulting in reduced systemic toxicity and improved bioavailability.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different types of targeted delivery systems, such as nanoparticles or liposomes, or combining the selective inhibitor with other anti-cancer agents. Variations of the pharmaceutical composition could include different carrier molecules or excipients to further enhance bioavailability.
Potential Commercial Applications and Market
The enhanced selective inhibitors of exon 20 insertion mutant EGFR have significant commercial potential in the cancer treatment market, particularly in the area of non-small cell lung cancer (NSCLC). The targeted delivery system and improved formulations could provide a competitive advantage in the market, and the diagnostic kit could also generate revenue through sales to research institutions and hospitals.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/519 |
| A | A61 | A61P35/00 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Oncology pharmacology and targeted cancer therapeutics, specifically focused on EGFR mutation-based treatments with expertise in molecular diagnostics and pharmaceutical formulation
Person of Ordinary Skill (PHOSITA) Profile
A skilled researcher with advanced degrees in molecular biology or pharmacology, experienced in cancer therapeutics, familiar with targeted drug delivery systems, mutation detection techniques, and pharmaceutical formulation strategies
Obviousness Rationale
A person skilled in the art would recognize that the PTD's variations represent predictable extensions of the source patent's core technology, involving standard pharmaceutical engineering techniques for improving drug delivery and patient selection. The proposed targeted delivery and diagnostic methods are logical progressions from the original selective EGFR inhibitor concept, utilizing well-established approaches in precision oncology.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,513 |
|---|---|
| Title | Selective inhibitor of exon 20 insertion mutant EGFR |
| Assignee(s) | TAIHO PHARMACEUTICAL CO., LTD. |